

# European Health Economic Trial on Home Monitoring in ICD Patients

www.clinicaltrials.gov NCT00776087

Fast-Track publication in European Heart Journal

Prof. Dr. Hein Heidbuchel
Hasselt University & Heart Center Hasselt, Belgium
on behalf of the EuroEco investigators

Hot Line Session III - ESC Congress, September 1st 2014





#### Disclosures

H. Heidbuchel: Unconditional Research Grants through the University of Leuven from Medtronic, St. Jude Medical, BIOTRONIK and Boston Scientific.

Other authors: as listed in the Fast-Track Eur Heart J manuscript

The sponsor of the trial was BIOTRONIK.

www.clinicaltrials.gov NCT00776087



### Background



- All stakeholders see potential benefits in remote monitoring based device follow-up
  - patients<sup>1-2,5</sup>
  - physicians and hospitals ("providers")<sup>2-3</sup>
  - insurance payers of health care<sup>4-6</sup>
- A formal cost-analysis from the provider viewpoint has never been performed
  - although it may influence willingness to change care models

### EuroEco A health economic trial




- Primary endpoint:
  - Total follow-up related cost for providers (hospitals, physicians)
     classical (i.e. only in-office visits) vs. Home Monitoring based
- Secondary endpoints:
  - Impact of Home Monitoring on the net income of providers
  - Total cost from a healthcare payer perspective
  - In-office visits with relevant findings
  - Quality-of-life (SF-36)

### Study design /1



New or replacement VVI or DDD ICD\*



	<u>Ctrs</u>	<u>Pts</u>
DE	4	88
BE ES	3 4	87 54
_S JK	3	47
VL	1	25
=I	1	2
	17	303


\*:

Replacement: 12%

Capable of
HomeMonitoring
with electrogram
transmission
(BIOTRONIK Lumos
n=3 or Lumax)

# Study design /2 24 month follow-up





Termination before 24 month visit:

21.2%

NS

22.4%

Follow-up before termination:

10.2  $\pm$ 7.5 m

NS

13.8  $\pm$ 9.0m

Note: Extension CRT-cohort (n=104) is still enrolling

## Study design /3 Resource utilisation



- FU visits
- Patient contacts outside of FU services (phone calls)
- Internal discussions among staff
- Remote data review (monitoring)

For each: frequency, type of staff involved, staff time

Provider cost


- FU services if reimbursed
- Examinations initiated during FU services
- Other CV health care utilisation (other physician visits, hospitalisations)

Payer cost

#### Time measurement tools —— Euro Eco



Blackberry phones, dedicated chronometers, Web-based time tracking tool:



=> paper CRF

### Monetary valuation



- Country specific
  - staff costs
  - overhead
  - reimbursement tariffs (DRG or fee-for-service)
  - consumer price index for conversion to 2013 Euro
- Remote monitoring equipment was not included
- Since only 2 patients from Finland: no monetary valuation
- Exploratory analysis comparing countries with different reimbursement systems
  - 2 sets of countries with homogeneous resource utilisation

### Baseline characteristics — Euro Eco





	Total cohort (N=303)		
	HM OFF (N=144)	HM ON (N=159)	р
Age [years, mean] (SD)	62.9 (12.3)	62.0 (13.9)	NS
Male [%]	83.3	78.0	NS
Primary prevention [%]	44.1	57.0	0.029
Single chamber [%]	60.8	59.7	NS
LVEF [%] (SD)	39.5 (15.6)	39.2 (14.8)	NS
NYHA profile [%]			NS
No heart failure	19.4	19.5	
I	18.1	23.3	
II	39.6	34.6	
III	13.2	10.7	
IV	0.7	1.3	

Abbreviations: FU, follow up; HM, Home Monitoring; SD, standard deviation

# Resource utilisation /1 Provider perspective









# Resource utilisation /2 Payer perspective






### Total staff time for follow-up —— Euro Eco






### Total staff time for follow-up —— Euro Eco






# Primary endpoint Provider cost for follow-up






# Secondary endpoints /1 Payer cost





#### Secondary endpoints /2 Provider net income






Abbreviations: FU. Follow-up; HM, Home Monitoring Notes: All data in Euro, as mean per patient. Patients from Finland excluded due to small number (n=2).


## Country dependent variations Provider perspective





## Country dependent variations Payer perspective





Even in countries with remote monitoring reimbursement (UK and Germany), total costs for insurers over 2 years of follow-up do not increase.

#### **Conclusions**



- EuroEco population as a whole:
  - provider costs are equal when FU is based on Home Monitoring
    - despite saving on office visits and physician time
    - increasing other contacts (calls; discussions; remote sessions), handled by others.
  - payer costs are not significantly different (with a trend to be lower)
- Country analysis shows important impact of reimbursement
  - provider income increases or decreases
    - which may incentivise reorganisation towards remote monitoring based FU or not
  - payer costs do not increase, even with reimbursement present
    - allowing room for equipment reimbursement (not included in EuroEco analysis)
- EuroEco may facilitate discussions towards balanced reimbursement, benefiting all:
  - industry, physicians, insurers
  - while providing patients more continuous care



## I thank you and the Investigators



European Heart Journal doi:10.1093/eurhearti/ehu339 **ESC HOT LINE** 

Arrhythmia/electrophysiology

EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring

Hein Heidbuchel<sup>1\*</sup>, Gerd Hindricks<sup>2</sup>, Paul Broadhurst<sup>3</sup>, Lieselot Van Erven<sup>4</sup>, Ignacio Fernandez-Lozano<sup>5</sup>, Maximo Rivero-Ayerza<sup>6</sup>, Klaus Malinowski<sup>7</sup>, Andrea Marek<sup>8</sup>, Rafael F. Romero Garrido<sup>9</sup>, Steffen Löscher<sup>10</sup>, Ian Beeton<sup>11</sup>, Enrique Garcia<sup>12</sup>, Stephen Cross<sup>13</sup>, Johan Vijgen<sup>1</sup>, Ulla-Maija Koivisto<sup>14</sup>, Rafael Peinado<sup>15</sup>, Antje Smala<sup>16</sup>, and Lieven Annemans<sup>17</sup>